AstraZeneca PLC

AstraZeneca PLC a biopharmaceutical company focuses on the discovery development manufacture and commercialization of prescription medicines. The company's marketed products include Calquence Enhertu Faslodex Imfinzi Iressa Koselugo Lumoxiti Lynparza Orpathys Tagrisso and Zoladex for oncology; Andexxa/Ondexxya Atacand Atacand HCT Atacand Plus Brilinta/Brilique Bydureon/Byetta BCise Byetta Crestor Evrenzo Farxiga/Forxiga Komboglyze/Kombiglyze XR Lokelma Onglyza Qtern Xigduo/Xigduo and Zestril XR for cardiovascular renal and metabolism diseases; Accolate Accoleit Vanticon Bevespi Aerosphere Breztri Aerosphere Bricanyl Respules and Turbuhaler Daliresp/Daxas Duaklir Genuair Fasenra Pulmicort Rhinocort Saphnelo Symbicort and Tezspire for respiratory and immunology; and Kanuma Soliris Strensiq and Ultomiris for rare diseases. Its marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom rest of Europe the Americas Asia Africa and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; and Personalis Inc as well as research collaboration with Sernova Corp. to evaluate novel potential therapeutic cell applications; and collaboration with Cholesgen (Shanghai) Co.Ltd. to advance research and development in hypercholesterolemia and related metabolic diseases. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge the United Kingdom.